Pulmonx Co. (NASDAQ:LUNG) General Counsel Sells $32,730.41 in Stock

Pulmonx Co. (NASDAQ:LUNG) General Counsel David Aaron Lehman sold 10,457 shares of the company’s stock in a transaction on Monday, June 2nd. The stock was sold at an average price of $3.13, for a total transaction of $32,730.41. Following the sale, the general counsel now directly owns 273,039 shares of the company’s stock, valued at $854,612.07. The trade was a 3.69% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Pulmonx Price Performance

LUNG stock opened at $3.17 on Friday. The company has a market capitalization of $127.62 million, a P/E ratio of -2.20 and a beta of 0.52. Pulmonx Co. has a twelve month low of $2.83 and a twelve month high of $9.37. The business has a 50 day simple moving average of $4.27 and a 200-day simple moving average of $5.95. The company has a current ratio of 7.70, a quick ratio of 6.77 and a debt-to-equity ratio of 0.40.

Pulmonx (NASDAQ:LUNG) last issued its quarterly earnings results on Wednesday, May 7th. The company reported ($0.36) earnings per share for the quarter, topping the consensus estimate of ($0.37) by $0.01. Pulmonx had a negative return on equity of 55.36% and a negative net margin of 67.31%. The firm had revenue of $22.54 million during the quarter, compared to the consensus estimate of $22.03 million. As a group, equities analysts anticipate that Pulmonx Co. will post -1.55 EPS for the current year.

Institutional Investors Weigh In On Pulmonx

Hedge funds and other institutional investors have recently bought and sold shares of the business. SG Americas Securities LLC increased its position in shares of Pulmonx by 27.0% in the fourth quarter. SG Americas Securities LLC now owns 15,555 shares of the company’s stock valued at $106,000 after buying an additional 3,310 shares in the last quarter. Rhumbline Advisers increased its position in shares of Pulmonx by 4.9% in the fourth quarter. Rhumbline Advisers now owns 53,503 shares of the company’s stock valued at $363,000 after buying an additional 2,488 shares in the last quarter. Charles Schwab Investment Management Inc. increased its position in shares of Pulmonx by 0.8% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 315,532 shares of the company’s stock valued at $2,142,000 after buying an additional 2,363 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. increased its position in shares of Pulmonx by 44.8% in the fourth quarter. Connor Clark & Lunn Investment Management Ltd. now owns 83,941 shares of the company’s stock valued at $570,000 after buying an additional 25,988 shares in the last quarter. Finally, American Century Companies Inc. increased its position in shares of Pulmonx by 8.8% in the fourth quarter. American Century Companies Inc. now owns 34,738 shares of the company’s stock valued at $236,000 after buying an additional 2,810 shares in the last quarter. Institutional investors and hedge funds own 91.04% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on the stock. Canaccord Genuity Group lowered their price target on shares of Pulmonx from $16.00 to $15.00 and set a “buy” rating on the stock in a research report on Thursday, May 1st. Piper Sandler reissued an “overweight” rating and set a $9.00 price target (down previously from $10.00) on shares of Pulmonx in a research report on Thursday, May 1st. Morgan Stanley assumed coverage on shares of Pulmonx in a research report on Monday, March 10th. They set an “equal weight” rating on the stock. D. Boral Capital reissued a “buy” rating and set a $17.00 price target on shares of Pulmonx in a research report on Thursday, May 1st. Finally, Citigroup lowered their price target on shares of Pulmonx from $6.50 to $4.15 and set a “neutral” rating on the stock in a research report on Thursday, May 22nd. Three research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to data from MarketBeat, Pulmonx has a consensus rating of “Moderate Buy” and an average price target of $11.53.

About Pulmonx

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.